Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Laura E. Mead"'
Publikováno v:
Journal of Perinatology. 30:724-730
Endothelial progenitor cells (EPCs) have been examined in numerous adult diseases and have been suggested as a cellular-based therapy. However, there are no reports describing EPCs being isolated from newborn peripheral blood. Endothelial colony-form
Autor:
Jalees Rehman, Daniel N. Prater, M. Reza Saadatzadeh, Michael P. Murphy, David A. Ingram, Yanmin Zhang, Laura E. Mead
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 296:H1675-H1682
Cell therapy with endothelial progenitor cells (EPCs) is an emerging therapeutic option to promote angiogenesis or endothelial repair. Although the release of angiogenic paracrine factors is known to contribute to their therapeutic effect, little is
Autor:
Yanmin Zhang, Jalees Rehman, J. Michael Walker, Christiane A. Opitz, Mervin C. Yoder, David A. Ingram, Laura E. Mead, Neta Rimmerman
Publikováno v:
FEBS Letters. 581:4927-4931
Recent studies have highlighted the importance of paracrine growth factors as mediators of pro-angiogenic effects by endothelial progenitor cells (EPCs), but little is known about the release of lipid-based factors like endocannabinoids by EPCs. In t
Autor:
Xiaohua Wu, Amy Fenoglio, David A. Ingram, Hilary White, Shanbao Cai, Amy M. Munchhof, Fang Li, Shi Chen, Theresa R. Krier, Feng Chun Yang, Laura E. Mead
Publikováno v:
Human Molecular Genetics. 15:1921-1930
Neurofibromatosis type I (NF1) is a genetic disorder caused by mutations in the NF1 tumor suppressor gene. Neurofibromin is encoded by NF1 and functions as a negative regulator of Ras activity. NF1 patients develop renal artery stenosis and arterial
Autor:
Hilary White, David R. Williams, Mary Jo Wenning, Travis Clegg, Cynthia M. Hingtgen, David A. Ingram, Kelly R. Monk, Laura E. Mead, Nancy Ratner, Shi Chen, D. Wade Clapp, Reuben Kapur, Feng Chun Yang, Simon J. Atkinson
Publikováno v:
Journal of Clinical Investigation. 112:1851-1861
The NF1 tumor suppressor gene encodes a GTPase-activating protein called neurofibromin that negatively regulates Ras signaling. Mutations in NF1 cause neurofibromatosis type 1 (NF1). The development of neurofibromas, which are complex tumors composed
Autor:
Graça Almeida-Porada, Evan Colletti, Christopher D. Porada, Joshua A. Wood, Esmail D. Zanjani, Mervin C. Yoder, David A. Ingram, Laura E. Mead
Publikováno v:
Hepatology (Baltimore, Md.). 56(3)
While the vasculogenic potential of circulating and cord blood-derived endothelial colony-forming cells (ECFC) has been demonstrated in vitro and in vivo, little is known about the inherent biologic ability of these cells to home to different organs
Autor:
David A. Ingram, Merv Yoder, Laura E. Mead, Ryan Dhaemers, Marc S. Mendonca, Helen Chin-Sinex
Publikováno v:
Radiation research. 176(2)
Endothelial colony-forming cells (ECFCs) are endothelial progenitor cells that circulate at low concentration in human umbilical cord and adult peripheral blood and are largely resident in blood vessels. ECFCs not only appear to be critical for norma
Publikováno v:
Current Protocols in Stem Cell Biology
Circulating endothelial progenitor cells (EPCs) in adult human peripheral blood were originally identified in 1997 by Asahara et al., which challenged the paradigm that vasculogenesis is a process restricted to embryonic development. Since their orig
Autor:
Fang Li, Elisabeth A. Lasater, David A. Ingram, Simon J. Conway, D. Wade Clapp, Laura E. Mead, Waylan K. Bessler, Whitney Horn
Publikováno v:
Human molecular genetics. 17(15)
Neurofibromatosis type I (NF1) is a genetic disorder caused by mutations in the NF1 tumor suppressor gene. Neurofibromin is encoded by NF1 and functions as a negative regulator of Ras activity. Somatic mutations in the residual normal NF1 allele with
Autor:
David R. Foster, Daniel N. Prater, Mervin C. Yoder, W. Scott Goebel, M Jawad Javed, Waylan K. Bessler, Jamie Case, Laura S. Haneline, David A. Ingram, Laura E. Mead
Publikováno v:
Pediatric research. 64(1)
Endothelial progenitor cells (EPCs) are used for angiogenic therapies and as biomarkers of cardiovascular disease. Human umbilical cord blood (UCB) is a rich source of endothelial colony forming cells (ECFCs), which are EPCs with robust proliferative